☰
✕
Home/ Healthcare/ Global Alpha And Beta Emitters Based Radiopharmaceuticals Market
Request for TOC Request for Sample
BUY NOW

Global Alpha and Beta Emitters Based Radiopharmaceuticals Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Healthcare | Published Report | Jun 2025 | Global | 350 Pages | No of Tables: 428 | No of Figures: 47
Buy Now Request for Sample
Nucleus

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Global Alpha And Beta Emitters Based Radiopharmaceuticals Market

Market Size in USD Billion

CAGR :  %

USD 801.45 Million USD 1,769.20 Million 2024 2032
Forecast Period
 2025 –2032
Market Size(Base Year)
USD 801.45 Million
Market Size (Forecast Year)
 USD 1,769.20 Million
CAGR
 %
Major Markets Players
  • Novartis AG
  • Eckert & Ziegler
  • ITM Isotope Technologies Munich SE
  • SHINE Technologies LLC
  • Actinium Pharmaceuticals Inc.

Global Alpha and Beta Emitters Based Radiopharmaceuticals Market Segmentation, By Isotope (Beta Emitters and Alpha Emitters), Sources (Reactor-Produced Isotopes, Generator-Produced Isotopes, and Others), Therapeutic Application (Oncology and Others), Vector Type (Small Molecule Ligands, Peptides, Monoclonal Antibodies, and Others), End User (Hospitals, Radiopharmacies, and Research Institutes) - Industry Trends and Forecast to 2032

Get Exclusive Sample Copy of this Report Here

Alpha and Beta Emitters Based Radiopharmaceuticals Market Size

  • The global alpha and beta emitters based radiopharmaceuticals market size was valued at USD 801.45 million in 2024 and is expected to reach USD 1,769.20 million by 2032, at a CAGR of 10.4% during the forecast period

  • The market growth is largely fueled by the increased efficacy of targeted alpha and beta therapies

  • Furthermore, growing adoption of theranostics in personalized medicine. These converging factors are accelerating the uptake of alpha and beta emitters based radiopharmaceuticals solutions, thereby significantly boosting the industry's growth

Get Exclusive Sample Copy of this Report Here
Get Exclusive Sample Copy of this Report Here

Alpha and Beta Emitters Based Radiopharmaceuticals Market Analysis

  • Alpha and beta emitters based radiopharmaceuticals are increasingly recognized for their precision in targeted therapy, especially in oncology and nuclear medicine, providing effective diagnosis and treatment options with minimal side effects

  • The rising incidence of cancer worldwide, along with growing awareness about personalized medicine and advancements in radiopharmaceutical technology, is driving global demand for alpha and beta emitters based radiopharmaceuticals

  • North America holds a significant share in the global alpha and beta emitters based radiopharmaceuticals market, accounting for approximately 42.59% share of the revenue in 2025, supported by advanced healthcare infrastructure, extensive R&D activities, and early adoption of novel therapeutic technologies

  • North America region is anticipated to be the fastest-growing market for alpha and beta emitters based radiopharmaceuticals during the forecast period, propelled by expanding healthcare infrastructure, increasing cancer prevalence, government initiatives for healthcare improvement

  • The beta emitters segment is expected to dominate the market with a share of 84.78% in 2025, driven by their high efficacy in Targeted Alpha Therapy (TAT), improved patient outcomes, and rising research focused on alpha-emitting isotopes like Actinium-225 and Radium-223 for cancer treatment

Report Scope and Alpha and Beta Emitters Based Radiopharmaceuticals Market Segmentation  

Attributes

Alpha and Beta Emitters Based Radiopharmaceuticals Key Market Insights

Segments Covered

  • By Isotope: Beta Emitters and Alpha Emitters

  • By Sources: Reactor-Produced Isotopes, Generator-Produced Isotopes, and Others

  • By Therapeutic Application: Oncology and Others

  • By Vector Type: Small Molecule Ligands, Peptides, Monoclonal Antibodies, and Others

  • By End User: Hospitals, Radiopharmacies, and Research Institutes

Countries Covered

North America

  • U.S.

  • Canada

  • Mexico

Asia-Pacific

  • China

  • Australia

  • Japan

  • South Korea

  • Singapore

  • India

  • Indonesia

  • Philippines

  • Thailand

  • Malaysia

  • Vietnam

  • Taiwan

  • Rest of Asia-Pacific

Europe

  • Germany

  • U.K.

  • France

  • Italy

  • Spain

  • Poland

  • Russia

  • Norway

  • Turkey

  • Austria

  • Ireland

  • Netherlands

  • Switzerland

  • Rest of Europe

South America

  • Brazil

  • Argentina

  • Chile

  • Peru

  • Rest of South America

Middle East and Africa

  • South Africa

  • Egypt

  • Saudi Arabia

  • U.A.E.

  • Kuwait

  • Israel

  • Rest of Middle East and Africa

Key Market Players

  • Novartis AG (Switzerland)

  • Eckert & Ziegler (Germany)

  • ITM Isotope Technologies Munich SE (Germany)

  • SHINE Technologies, LLC (U.S.)

  • Actinium Pharmaceuticals, Inc. (U.S.)

  • Alpha Tau Medical Ltd. (Israel)

  • ARICEUM THERAPEUTICS (Germany)

  • Bayer AG (Germany)

  • Curium (U.S.)

  • IONETIX Corporation (U.S.)

  • Isotopia (Israel)

  • Lantheus (U.S.)

  • Lilly (U.S.)

  • Niowave (U.S.)

  • NMR (U.S.)

  • Oncoinvent (Norway)

  • Orano Group (Paris)

  • Radiopharm Theranostics Limited (Australia)

  • Telix Pharmaceuticals Limited (Australia)

  • Terthera (Netherlands)

Market Opportunities

  • Surge in R&D activity expanding radiopharmaceutical applications

  • Expansion of Lu-177-PSMA therapy in prostate cancer treatment

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Alpha and Beta Emitters Based Radiopharmaceuticals Market Trends

“Increased Efficacy of Targeted Alpha and Beta Therapies”

  • A major driving force behind the global alpha and beta emitters based radiopharmaceuticals market is the increasing clinical adoption of targeted radionuclide therapies, owing to their proven efficacy in treating advanced cancers such as neuroendocrine tumors and metastatic castration-resistant prostate cancer (mCRPC)

  • For instance, in May 2023, according to the article published by NCBI, the approved [177Lu]Lu-PSMA-617 regimen (7.4 GBq per cycle every 6 weeks for up to 6 cycles) has shown strong safety and anti-tumor efficacy in real-world use, with flexible dosing (6–9.3 GBq) and treatment intervals (4–10 weeks). This consistent clinical performance enhances physician confidence and accelerates market adoption

  • Radiopharmaceuticals like Lu-177, particularly when used in peptide receptor radionuclide therapy (PRRT), have demonstrated remarkable success in the treatment of neuroendocrine tumors, delivering potent beta radiation directly to tumor sites while preserving healthy tissues—leading to improved outcomes and increased demand

  • Technological advancements and clinical validation of alpha-emitting isotopes, such as Ac-225, have further propelled the market. Ac-225 has proven highly effective in targeting prostate cancer cells resistant to traditional therapies, with minimal side effects and strong therapeutic impact

Alpha and Beta Emitters Based Radiopharmaceuticals Market Dynamics

Driver

“Growing Adoption of Theranostics in Personalized Medicine”

  • The increasing adoption of theranostic alpha- and beta-emitter radiopharmaceuticals—such as Lutetium-177 (Lu-177) and Terbium-161 (Tb-161)—is a major driver propelling the Global radiopharmaceuticals market. By pairing diagnostic imaging with targeted therapy in a single clinical workflow, these agents deliver precise, patient-specific care that improves outcomes and streamlines treatment planning

  • For instance, in July 2023, a review published in NCBI reported rising clinical use of Lu-177–based theranostic regimens (e.g., ¹⁷⁷Lu-DOTATATE for neuroendocrine tumors and ¹⁷⁷Lu-PSMA for prostate cancer). FDA approvals for these agents validated their safety and efficacy, accelerating adoption and highlighting the powerful synergy of matched diagnostic–therapeutic pairs

  • Growing awareness among oncologists and nuclear-medicine specialists of the workflow efficiency, treatment accuracy, and reduced toxicity associated with theranostic approaches is driving demand, as clinicians seek reliable tools for personalized cancer management

  • Furthermore, as healthcare systems face mounting pressures to improve survival rates and control costs, integrated imaging-therapy solutions like Lu-177 and Tb-161 reduce time to treatment, avoid ineffective interventions, and enhance quality of life—solidifying their value proposition

  • The rising preference for precision oncology, coupled with ongoing R&D in next-generation isotopes such as Tb-149, Tb-152/155, and Ac-225, positions theranostic radiopharmaceuticals as a cornerstone of modern cancer care and a key growth engine for the global market

Restraint/Challenge

“Supply Chain and Scalability Challenges from Short Isotope Half-Lives”

  • The short half-life of radionuclides such as Lead-212 (~10.6 hours) creates major logistical and operational hurdles: production must occur close to treatment sites, transport windows are only a few hours, and highly coordinated “just-in-time” supply chains are required—collectively constraining large-scale manufacturing and market reach

  • For instance, in April 2025 L.E.K. Consulting noted that Pb-212’s 10.6-hour half-life forces decentralized, near-patient production and on-site generator infrastructure, limiting economies of scale and complicating distribution logistics

  • Furthermore, the intricate generator systems needed to extract Pb-212 (and other short-lived isotopes) add layers of regulatory compliance, radiation-safety requirements, and capital expenditure, making broad deployment difficult for hospitals and radiopharmacies

  • While advances in compact generators, faster purification methods, and regional production hubs could eventually ease these pressures, the fundamental time-sensitive nature of short-lived isotopes remains a significant restraint on the widespread adoption and growth of the radiopharmaceuticals market

Get Exclusive Sample Copy of this Report Here

Alpha and Beta Emitters Based Radiopharmaceuticals Market Scope

The market is segmented on the basis of isotope, sources, therapeutic application, vector type, and end user.

  • By Isotope

On the basis of isotope type, the market is segmented into beta emitters and alpha emitters. In 2025, the beta emitters segment is expected to dominate the market with the 84.78% market share, owing to the widespread clinical adoption of isotopes such as Lutetium-177 (Lu-177) and Yttrium-90 (Y-90) for treating neuroendocrine tumors, liver cancer, and prostate cancer. Beta emitters are preferred for their relatively longer half-lives, established safety profiles, and compatibility with existing clinical workflows.

The beta emitters segment is projected to witness the fastest growth rate of 9.1% from 2025 to 2032, driven by increasing usage of Actinium-225 (Ac-225) and Lead-212 (Pb-212) in advanced cancer treatments. Alpha emitters offer high linear energy transfer (LET) and greater tumor-killing efficacy with minimal collateral damage, making them highly suitable for resistant and metastatic cancers.

  • By Sources

On the basis of sources, the market is categorized into reactor-produced isotopes, generator-produced isotopes, and others. In 2025, reactor-produced isotopes will lead the market due to the high-volume supply and broad availability of key beta emitters such as Lu-177 and Iodine-131.

However, reactor-produced isotopes are expected to be the fastest-growing segment, propelled by increasing demand for isotopes like Pb-212 and Ra-223, which require decentralized and near-patient production. The rise of on-site generators also aligns with the growing interest in alpha therapies and short-lived radiopharmaceuticals.

  • By Therapeutic Application

On therapeutic application, the market is segmented into oncology and others. In 2025, oncology dominates the market, as radiopharmaceuticals play a central role in targeted therapies for prostate cancer, neuroendocrine tumors, and lymphoma. The increasing success of PSMA-targeted and PRRT-based therapies reinforces the leadership of oncology in this space.

The oncology segment includes cardiovascular, endocrine, and neurological disorders and is anticipated to witness steady growth with the development of novel radioligands and expansion into non-oncologic indications.

  • By Vector Type

On the basis of vector type, the market is segmented into small molecule ligands, peptides, monoclonal antibodies, and others. In 2025, small molecule ligands are expected to hold the largest market share due to their rapid tissue penetration and widespread use in PSMA and somatostatin-targeted therapies.

Small molecule ligands are poised for significant growth during the forecast period due to advances in conjugation technologies and their ability to offer enhanced tumor selectivity, longer circulation times, and improved binding efficiency. These vectors are especially critical for alpha emitter therapies where precision is paramount.

  • By End User

On the basis of, the market is segmented by end user into hospitals, radiopharmacies, and research institutes. In 2025, hospitals will account for the largest share, driven by increasing patient access to nuclear medicine, growth of theranostic departments, and strong reimbursement frameworks in developed countries.

The radiopharmacies segment is expected to grow rapidly due to the rising demand for centralized and decentralized compounding of radiopharmaceuticals, especially those with short half-lives. Research institutes will continue to play a vital role in innovation and clinical trials, particularly for next-generation isotopes like Terbium-161 and Actinium-225.

Get Exclusive Sample Copy of this Report Here

Alpha and Beta Emitters Based Radiopharmaceuticals Market Regional Analysis

  • North America dominates the alpha- and beta-emitters–based radiopharmaceuticals market with the largest revenue share of 42.59% in 2025 and is projected to expand at a robust CAGR through 2032

  • Underpinned by deep oncology pipelines, rapid theranostic uptake, and a dense network of PET/SPECT and radiopharmacy facilities. The region’s strong federal funding for nuclear-medicine research, favorable reimbursement for radioligand therapy, and continual investments by producers of Lu-177 and Ac-225 establish a resilient domestic supply chain and sustain market leadership

  • Major economies such as the United States and Canada leverage mature isotope-production infrastructure, extensive clinical-trial activity, and public-private partnerships to scale manufacturing and enable rapid patient access

U.S. Alpha and Beta Emitters Based Radiopharmaceuticals Market Insight

The U.S. holds the major share of North America revenue in 2025, driven by an advanced healthcare ecosystem, early FDA approvals (e.g., Lu-177 PSMA-617), and ongoing capacity expansions by suppliers such as PharmaLogic and SHINE.

Canada Alpha and Beta Emitters Based Radiopharmaceuticals Market Insight

Canada posts double-digit growth as new cyclotron and reactor upgrades support domestic Lu-177 output, while a widening network of outpatient theranostic centres meets rising demand for precision oncology.

Asia-Pacific Alpha and Beta Emitters Based Radiopharmaceuticals Market Insight

Asia-Pacific is the growing region, capturing significant share of global revenues in 2025, spurred by surging cancer incidence, large patient pools, and aggressive government investment in nuclear-medicine capacity. National cancer-control programmes, expanding cyclotron fleets, and the localisation of Lu-177 and Ac-225 production underpin the region’s momentum, while improving reimbursement widens patient access. Major economies China, India, Japan, and South Korea are rapidly scaling radiopharmaceutical manufacturing through state-led initiatives and collaborations with global isotope suppliers.

China Alpha and Beta Emitters Based Radiopharmaceuticals Market Insight

China commands the largest Asia-Pacific share in 2025, propelled by a strategic focus on domestic isotope self-sufficiency and joint ventures (e.g., IBA proton-therapy and isotope collaborations with CGN) that reinforce supply-chain security.

India Alpha and Beta Emitters Based Radiopharmaceuticals Market Insight

India records the region’s quickest growth pace thanks to Department of Atomic Energy programmes that have scaled indigenous Lu-177 and PSMA-ligand production at BARC, sharply reducing import dependence and boosting therapy volumes.

South Korea Alpha and Beta Emitters Based Radiopharmaceuticals Market Insight

South Korea’s science ministry roadmap to foster a radiopharmaceutical export industry by 2035—including domestic Lu-177 production—positions the country for high mid-term growth and regional supply-hub status.

Europe Alpha and Beta Emitters Based Radiopharmaceuticals Market Insight

Europe accounts for just over one-quarter of global revenues (≈ 25 %) in 2025 and is projected to grow at a steady CAGR through 2032, supported by stringent environmental and quality regulations that favor in-house isotope generation and widespread adoption of theranostics. EU-funded research consortia, pan-European trials of Ac-225 and Tb-161 compounds, and rapid expansion of centralized radiopharmacies bolster regional growth, while the EU’s EURATOM framework secures reactor-sourced isotope supply.

Economies such as Germany, France, and the U.K. lead in theranostic installations, GMP production lines, and clinical research networks.

Germany Alpha and Beta Emitters Based Radiopharmaceuticals Market Insight

Germany tops European revenues in 2025, buoyed by its dense network of nuclear-medicine clinics, investment incentives for GMP Lu-177 plants, and ongoing growth of imaging-therapy centres—lifting market value toward USD 39.29 million by 2024.

France Alpha and Beta Emitters Based Radiopharmaceuticals Market Insight

France shows solid expansion as climate-resilient healthcare policy encourages low-dose, high-efficacy therapies, and clusters around Orano and CEA channel funding into next-generation alpha-emitter programs and decentralized generator deployment.

Get Exclusive Sample Copy of this Report Here

Alpha and Beta Emitters Based Radiopharmaceuticals Market Share

The alpha and beta emitters based radiopharmaceuticals market is primarily led by well-established companies, including:

  • Novartis AG (Switzerland)

  • Eckert & Ziegler Germany)

  • ITM Isotope Technologies Munich SE (Germany)

  • SHINE Technologies, LLC (U.S.)

  • Actinium Pharmaceuticals, Inc. (U.S.)

  • Alpha Tau Medical Ltd. (Israel)

  • ARICEUM THERAPEUTICS (Germany)

  • Bayer AG (Germany)

  • Curium (U.S.)

  • IONETIX Corporation (U.S.)

  • Isotopia (Israel)

  • Lantheus (U.S.)

  • Lilly (U.S.)

  • Niowave (U.S.)

  • NMR (U.S.)

  • Oncoinvent (Norway)

  • Orano Group (Paris)

  • Radiopharm Theranostics Limited (Australia)

  • Telix Pharmaceuticals Limited (Australia)

  • Terthera (Netherlands)

Latest Developments in Alpha and Beta Emitters Based Radiopharmaceuticals Market

  • In May 2025, ITM Isotope Technologies Munich SE and Radiopharm Theranostics announced a supply agreement for non-carrier-added Lutetium-177 (n.c.a. 177Lu). The partnership supports Radiopharm’s clinical development of Lu-177-based therapies, including RAD 204, RAD 202, and RV01, ensuring high-quality isotope access for targeted radiopharmaceutical treatment of solid tumors in ongoing and future clinical trials

  • In March 2025, the FDA approved Novartis’ Pluvicto (Lu-177 vipivotide tetraxetan) for earlier use in PSMA-positive metastatic castration-resistant prostate cancer, allowing administration after one ARPI and before chemotherapy. Based on Phase III PSMAfore trial results, Pluvicto reduced progression or death risk by 59%, doubling median radiographic progression-free survival while maintaining a favorable safety profile and expanding patient access significantly

  • In March 2025, Eckert & Ziegler and AtomVie Global Radiopharma signed a Global supply agreement for non-carrier added Lutetium-177 (Theralugand). The partnership ensures a stable, high-quality Lu-177 supply for AtomVie’s CDMO radiopharmaceutical operations, supporting early-to-late-stage development worldwide and enhancing both companies' capabilities in radiopharmaceutical innovation, regulatory compliance, and patient-centered nuclear medicine solutions

  • In March 2025, Eckert & Ziegler and Actinium Pharmaceuticals signed a supply agreement for high-purity Actinium-225 (Ac-225). The partnership ensures a reliable Ac-225 source to support the development of Actimab-A and other radiotherapeutic candidates targeting AML and solid tumors, strengthening Actinium’s clinical pipeline and addressing Global isotope supply challenges in precision radiopharmaceutical therapy

  • In May 2024, Novartis AG announced its agreement to acquire Mariana Oncology for USD 1 billion upfront and up to USD 750 million in milestone payments. The acquisition strengthens Novartis’ radioligand therapy (RLT) pipeline with preclinical assets targeting solid tumors, including actinium-based candidate MC-339 for small cell lung cancer, and enhances its RLT research, supply, and innovation capabilities

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET

1.4 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELLING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 VENDOR SHARE ANALYSIS

2.1 END USER MARKET COVERAGE GRID

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHT

4.1 PORTER’S FIVE FORCES

4.2 PESTEL ANALYSIS

4.3 PIPELINE

4.4 SUPPLY CHAIN ECOSYSTEM

4.4.1 PROMINENT COMPANIES

4.4.2 SMALL & MEDIUM SIZE COMPANIES

4.4.3 END USERS

4.5 INDUSTRY INSIGHTS:

4.5.1 MICRO AND MACRO ECONOMIC FACTORS

4.5.2 KEY PRICING STRATEGIES

4.6 MARKETED DRUG ANALYSIS

4.6.1 DRUG

4.6.1.1 BRAND NAME

4.6.1.2 GENERIC NAME

 

4.6.2 THERAPEUTIC INDICATION

4.6.3 PHARMACOLOGICAL CLASS OF THE DRUG

4.6.4 DRUG PRIMARY INDICATION

4.6.5 MARKET STATUS

4.6.6 MEDICATION TYPE

4.6.7 DRUG DOSAGE FORM

4.6.8 DOSAGES AVAILABILITY

4.6.9 PACKAGING TYPE

4.6.10 DRUG ROUTE OF ADMINISTRATION

4.6.11 DOSING FREQUENCY

4.6.12 DRUG INSIGHT

4.6.13 OVERVIEW OF DRUG DEVELOPMENT ACTIVITIES

4.6.13.1 FORECAST MARKET OUTLOOK

4.6.13.2 CROSS COMPETITION

4.6.13.3 THERAPEUTIC PORTFOLIO

4.6.13.4 CURRENT DEVELOPMENT SCENARIO

4.7 HEALTHCARE TARIFFS IMPACT ANALYSIS

4.7.1 OVERVIEW

4.7.2 TARIFF STRUCTURES

4.7.2.1 GLOBAL VS. REGIONAL TARIFF STRUCTURES

4.7.2.2 UNITED STATES: MEDICARE/MEDICAID TARIFF POLICIES, CMS PRICING MODELS

4.7.2.3 EUROPEAN UNION: CROSS-BORDER TARIFF REGULATIONS, REIMBURSEMENT POLICIES

4.7.2.4 ASIA-PACIFIC: GOVERNMENT-IMPOSED TARIFFS ON IMPORTED MEDICAL PRODUCTS

4.7.2.5 EMERGING MARKETS: CHALLENGES IN TARIFF IMPLEMENTATION

4.7.3 PHARMACEUTICAL TARIFFS AND TRADE BARRIERS

4.7.3.1 IMPORT DUTIES ON PRESCRIPTION DRUGS VS. GENERICS

4.7.3.2 IMPACT ON DRUG AFFORDABILITY AND ACCESS

4.7.3.3 KEY TRADE AGREEMENTS AFFECTING PHARMACEUTICAL TARIFFS

4.8 IMPACT OF HEALTHCARE TARIFFS ON PROVIDERS AND PATIENTS

4.8.1.1 COST BURDEN ON HOSPITALS AND HEALTHCARE FACILITIES

4.8.1.2 EFFECT ON PATIENT AFFORDABILITY AND INSURANCE COVERAGE

4.8.1.3 TARIFFS AND THEIR ROLE IN MEDICAL TOURISM

4.8.2 TRADE AGREEMENTS AND HEALTHCARE TARIFFS

4.8.2.1 WTO REGULATIONS ON HEALTHCARE TARIFFS

4.8.2.2 IMPACT OF TRADE WARS ON THE HEALTHCARE SUPPLY CHAIN

4.8.2.3 ROLE OF FREE TRADE AGREEMENTS (FTAS) IN REDUCING TARIFFS

4.8.3 IMPACT OF TARIFFS ON HEALTHCARE COSTS AND ACCESSIBILITY

4.8.4 IMPORTANCE OF TARIFFS IN THE HEALTHCARE SECTOR

4.9 EPIDEMIOLOGY OVERVIEW

4.9.1 INCIDENCE OF ALL CANCERS BY GENDER

4.9.2 TREATMENT RATE

4.9.3 MORTALITY RATE

4.9.4 DRUG ADHERENCE AND THERAPY SWITCH MODEL

4.9.5 PATIENT TREATMENT SUCCESS RATES

5 REGULATORY FRAMEWORK

5.1 REGULATORY FRAMEWORK OVERVIEW FOR THE NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET

5.1.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

5.1.2 REGULATORY APPROVAL PATHWAYS

5.1.3 LICENSING AND REGISTRATION

5.1.4 POST-MARKETING SURVEILLANCE

5.1.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

5.2 REGULATORY FRAMEWORK OVERVIEW FOR THE SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET

5.2.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

5.2.2 REGULATORY APPROVAL PATHWAYS

5.2.3 LICENSING AND REGISTRATION

5.2.4 POST-MARKETING SURVEILLANCE

5.2.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

5.3 REGULATORY FRAMEWORK OVERVIEW FOR THE EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET

5.3.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

5.3.2 REGULATORY APPROVAL PATHWAYS

5.3.3 LICENSING AND REGISTRATION

5.3.4 POST-MARKETING SURVEILLANCE

5.3.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

5.4 REGULATORY FRAMEWORK OVERVIEW FOR THE ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET

5.4.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

5.4.2 REGULATORY APPROVAL PATHWAYS

5.4.3 LICENSING AND REGISTRATION

5.4.4 POST-MARKETING SURVEILLANCE

5.4.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

5.5 REGULATORY FRAMEWORK OVERVIEW FOR THE MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET

5.5.1 GEOGRAPHIES’ EASE OF REGULATORY APPROVAL

5.5.2 REGULATORY APPROVAL PATHWAYS

5.5.3 LICENSING AND REGISTRATION

5.5.4 POST-MARKETING SURVEILLANCE

5.5.5 GOOD MANUFACTURING PRACTICES (GMPS) GUIDELINES

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES

6.1.2 GROWING ADOPTION OF THERANOSTICS IN PERSONALIZED MEDICINE

6.1.3 RISING CLINICAL DEMAND FOR ALPHA-BASED RADIOTHERAPIES

6.1.4 RISING CHRONIC DISEASE BURDEN DRIVING RADIOPHARMACEUTICAL DEMAND

6.2 RESTRAINTS

6.2.1 SUPPLY CHAIN AND SCALABILITY CHALLENGES FROM SHORT ISOTOPE HALF-LIVES

6.2.2 STRINGENT REGULATORY LANDSCAPE LIMITING MARKET FLEXIBILITY

6.2.3 SAFETY AND EXPOSURE RISKS IN RADIOPHARMACEUTICAL USE

6.3 OPPORTUNITIES

6.3.1 SURGE IN R&D ACTIVITY EXPANDING RADIOPHARMACEUTICAL APPLICATIONS

6.3.2 EXPANSION OF LU-177-PSMA THERAPY IN PROSTATE CANCER TREATMENT

6.3.3 STRATEGIC COLLABORATIONS DRIVING RADIOPHARMACEUTICAL INNOVATION

6.4 CHALLENGES

6.4.1 HIGH COST OF DEVELOPMENT AND IMPLEMENTATION OF RADIOPHARMACEUTICALS

6.4.2 SHORTAGE OF SKILLED WORKFORCE IN NUCLEAR MEDICINE AND RADIOCHEMISTRY

7 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE

7.1 OVERVIEW

7.2 BETA EMITTERS

7.2.1 LUTETIUM-177

7.2.2 TERBIUM-161

7.3 ALPHA EMITTERS

7.3.1 ACTINIUM-225

7.3.2 LEAD -212

8 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES

8.1 OVERVIEW

8.2 REACTOR-PRODUCED ISOTOPES

8.3 GENERATOR-PRODUCED ISOTOPES

8.4 OTHERS

 

9 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION

9.1 OVERVIEW

9.2 ONCOLOGY

9.2.1 PROSTATE CANCER

9.2.2 NEUROENDOCRINE TUMORS

9.2.3 LIVER CANCER

9.2.4 BRAIN TUMORS

9.2.5 BREAST CANCER

9.2.6 LEUKEMIA

9.3 OTHERS

10 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE

10.1 OVERVIEW

10.2 SMALL MOLECULE LIGANDS

10.3 PEPTIDES

10.4 MONOCLONAL ANTIBODIES

10.5 OTHERS

11 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER

11.1 OVERVIEW

11.2 HOSPITALS

11.2.1 ONCOLOGY CENTERS

11.2.2 NUCLEAR MEDICINE DEPARTMENTS

11.3 RADIOPHARMACIES

11.4 RESEARCH INSTITUTES

12 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION

12.1 OVERVIEW

12.2 NORTH AMERICA

12.2.1 U.S.

12.2.2 CANADA

12.2.3 MEXICO

 

12.3 EUROPE

12.3.1 GERMANY

12.3.2 U.K.

12.3.3 FRANCE

12.3.4 ITALY

12.3.5 SPAIN

12.3.6 POLAND

12.3.7 RUSSIA

12.3.8 NORWAY

12.3.9 TURKEY

12.3.10 AUSTRIA

12.3.11 IRELAND

12.3.12 NETHERLANDS

12.3.13 SWITZERLAND

12.3.14 REST OF EUROPE

12.4 ASIA PACIFIC

12.4.1 CHINA

12.4.2 AUSTRALIA

12.4.3 JAPAN

12.4.4 SOUTH KOREA

12.4.5 SINGAPORE

12.4.6 INDIA

12.4.7 INDONESIA

12.4.8 PHILIPPINES

12.4.9 THAILAND

12.4.10 MALAYSIA

12.4.11 VIETNAM

12.4.12 TAIWAN

12.4.13 REST OF ASIA-PACIFIC

12.5 SOUTH AMERICA

12.5.1 BRAZIL

12.5.2 ARGENTINA

12.5.3 CHILE

12.5.4 PERU

12.5.5 REST OF SOUTH AMERICA

 

12.6 MIDDLE EAST AND AFRICA

12.6.1 SOUTH AFRICA

12.6.2 EGYPT

12.6.3 SAUDI ARABIA

12.6.4 U.A.E.

12.6.5 KUWAIT

12.6.6 ISRAEL

12.6.7 REST OF MIDDLE EAST AND AFRICA

13 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY LANDSCAPE

13.1 COMPANY SHARE ANALYSIS: GLOBAL

13.2 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

13.3 COMPANY SHARE ANALYSIS: EUROPE

13.4 COMPANY SHARE ANALYSIS: NORTH AMERICA

14 SWOT ANALYSIS

15 COMPANY PROFILES

15.1 NOVARTIS AG

15.1.1 COMPANY SNAPSHOT

15.1.2 REVENUE ANALYSIS

15.1.3 COMPANY SHARE ANALYSIS

15.1.4 PRODUCT PORTFOLIO

15.1.5 RECENT DEVELOPMENTS

15.2 ECKERT & ZIEGLER

15.2.1 COMPANY SNAPSHOT

15.2.2 REVENUE ANALYSIS

15.2.3 COMPANY SHARE ANALYSIS

15.2.4 PRODUCT PORTFOLIO

15.2.5 RECENT DEVELOPMENTS

15.3 ITM ISOTOPE TECHNOLOGIES MUNICH SE

15.3.1 COMPANY SNAPSHOT

15.3.2 COMPANY SHARE ANALYSIS

15.3.3 PRODUCT PORTFOLIO

15.3.4 RECENT DEVELOPMENT

15.4 SHINE TECHNOLOGIES, LLC

15.4.1 COMPANY SNAPSHOT

15.4.2 COMPANY SHARE ANALYSIS

15.4.3 PRODUCT PORTFOLIO

15.4.4 RECENT DEVELOPMENT

15.5 ACTINIUM PHARMACEUTICALS, INC.

15.5.1 COMPANY SNAPSHOT

15.5.2 PIPELINE PRODUCT PORTFOLIO

15.5.3 RECENT DEVELOPMENTS

15.6 ALPHA TAU MEDICAL LTD.

15.6.1 COMPANY SNAPSHOT

15.6.2 PIPELINE PRODUCT PORTFOLIO

15.6.3 RECENT DEVELOPMENT

15.7 ARICEUM THERAPEUTICS

15.7.1 COMPANY SNAPSHOT

15.7.2 PIPELINE PRODUCT PORTFOLIO

15.7.3 RECENT DEVELOPMENT

15.8 BAYER AG

15.8.1 COMPANY SNAPSHOT

15.8.2 REVENUE ANALYSIS

15.8.3 PIPELINE PRODUCT PORTFOLIO

15.8.4 RECENT DEVELOPMENT

15.9 CURIUM

15.9.1 COMPANY SNAPSHOT

15.9.2 PIPELINE PRODUCT PORTFOLIO

15.9.3 RECENT DEVELOPMENT

15.1 IONETIX CORPORATION

15.10.1 COMPANY SNAPSHOT

15.10.2 PIPELINE PRODUCT PORTFOLIO

15.10.3 RECENT DEVELOPMENT

15.11 ISOTOPIA

15.11.1 COMPANY SNAPSHOT

15.11.2 PIPELINE PRODUCT PORTFOLIO

15.11.3 RECENT DEVELOPMENT

15.12 LANTHEUS

15.12.1 COMPANY SNAPSHOT

15.12.2 REVENUE ANALYSIS

15.12.3 PIPELINE PRODUCT PORTFOLIO

15.12.4 RECENT DEVELOPMENT

15.13 LILLY

15.13.1 COMPANY SNAPSHOT

15.13.2 REVENUE ANALYSIS

15.13.3 PIPELINE PRODUCT PORTFOLIO

 

15.14 NIOWAVE

15.14.1 COMPANY SNAPSHOT

15.14.2 PIPELINE PRODUCT PORTFOLIO

15.14.3 RECENT DEVELOPMENT

15.15 NMR

15.15.1 COMPANY SNAPSHOT

15.15.2 PIPELINE PRODUCT PORTFOLIO

15.15.3 RECENT DEVELOPMENT

15.16 ONCOINVENT

15.16.1 COMPANY SNAPSHOT

15.16.2 PIPELINE PRODUCT PORTFOLIO

15.16.3 RECENT DEVELOPMENT

15.17 ORANO GROUP

15.17.1 COMPANY SNAPSHOT

15.17.2 REVENUE ANALYSIS

15.17.3 PIPELINE PRODUCT PORTFOLIO

15.17.4 RECENT DEVELOPMENT

15.18 RADIOPHARM THERANOSTICS LIMITED

15.18.1 COMPANY SNAPSHOT

15.18.2 PIPELINE PRODUCT PORTFOLIO

15.18.3 RECENT DEVELOPMENT

15.19 TELIX PHARMACEUTICALS LIMITED

15.19.1 COMPANY SNAPSHOT

15.19.2 REVENUE ANALYSIS

15.19.3 PIPELINE PRODUCT PORTFOLIO

15.19.4 RECENT DEVELOPMENT

15.2 TERTHERA

15.20.1 COMPANY SNAPSHOT

15.20.2 PIPELINE PRODUCT PORTFOLIO

15.20.3 RECENT DEVELOPMENT

15.20.4 RECENT DEVELOPMENT

16 QUESTIONNAIRE

17 RELATED REPORTS

List of Table

TABLE 1 GLOBAL CLINICAL TRIAL MARKET FOR GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET

TABLE 2 DISTRIBUTION OF PRODUCTS AND PROJECTS BY PHASE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET

TABLE 3 DISTRIBUTION OF PROJECTS BY THERAPEUTIC AREA AND PHASE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET

TABLE 4 DISTRIBUTION OF PROJECTS BY SCIENTIFIC APPROACH AND PHASE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET

TABLE 5 PENETRATION AND GROWTH PROSPECT MAPPING

TABLE 6 INCIDENCE OF CANCER BY GENDER

TABLE 7 CANCER MORTALITY RATE

TABLE 8 CANCER TREATMENT SUCCESS RATE

TABLE 9 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 10 GLOBAL BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 11 GLOBAL BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 12 GLOBAL ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 13 GLOBAL ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 14 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 15 GLOBAL REACTOR-PRODUCED ISOTOPES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 16 GLOBAL GENERATOR-PRODUCED ISOTOPES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 17 GLOBAL OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 18 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 19 GLOBAL ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 20 GLOBAL ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 21 GLOBAL OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 22 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 23 GLOBAL SMALL MOLECULE LIGANDS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 24 GLOBAL PEPTIDES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 25 GLOBAL MONOCLONAL ANTIBODIES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 26 GLOBAL OTHERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 27 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 28 GLOBAL HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 29 GLOBAL HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 30 GLOBAL RADIOPHARMACIES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 31 GLOBAL RESEARCH INSTITUTES IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 32 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY REGION, 2018-2032 (USD THOUSAND)

TABLE 33 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 34 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 35 NORTH AMERICA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 36 NORTH AMERICA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 37 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 38 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 39 NORTH AMERICA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 40 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 41 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 42 NORTH AMERICA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 43 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 44 U.S. BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 45 U.S. ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 46 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 47 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 48 U.S. ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 49 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 50 U.S. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 51 U.S. HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 52 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 53 CANADA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 54 CANADA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 55 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 56 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 57 CANADA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 58 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 59 CANADA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 60 CANADA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 61 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 62 MEXICO BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 63 MEXICO ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 64 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 65 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 66 MEXICO ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 67 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 68 MEXICO ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 69 MEXICO HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 70 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 71 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 72 EUROPE BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 73 EUROPE ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 74 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 75 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 76 EUROPE ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 77 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 78 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 79 EUROPE HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 80 GERMANY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 81 GERMANY BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 82 GERMANY ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 83 GERMANY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 84 GERMANY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 85 GERMANY ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 86 GERMANY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 87 GERMANY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 88 GERMANY HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 89 U.K. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 90 U.K. BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 91 U.K. ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 92 U.K. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 93 U.K. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 94 U.K. ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 95 U.K. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 96 U.K. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 97 U.K. HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 98 FRANCE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 99 FRANCE BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 100 FRANCE ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 101 FRANCE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 102 FRANCE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 103 FRANCE ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 104 FRANCE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 105 FRANCE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 106 FRANCE HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 107 ITALY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 108 ITALY BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 109 ITALY ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 110 ITALY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 111 ITALY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 112 ITALY ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 113 ITALY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 114 ITALY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 115 ITALY HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 116 SPAIN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 117 SPAIN BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 118 SPAIN ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 119 SPAIN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 120 SPAIN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 121 SPAIN ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 122 SPAIN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 123 SPAIN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 124 SPAIN HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 125 POLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 126 POLAND BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 127 POLAND ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 128 POLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 129 POLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 130 POLAND ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 131 POLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 132 POLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 133 POLAND HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 134 RUSSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 135 RUSSIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 136 RUSSIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 137 RUSSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 138 RUSSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 139 RUSSIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 140 RUSSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 141 RUSSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 142 RUSSIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 143 NORWAY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 144 NORWAY BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 145 NORWAY ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 146 NORWAY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 147 NORWAY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 148 NORWAY ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 149 NORWAY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 150 NORWAY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 151 NORWAY HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 152 TURKEY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 153 TURKEY BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 154 TURKEY ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 155 TURKEY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 156 TURKEY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 157 TURKEY ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 158 TURKEY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 159 TURKEY ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 160 TURKEY HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 161 AUSTRIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 162 AUSTRIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 163 AUSTRIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 164 AUSTRIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 165 AUSTRIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 166 AUSTRIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 167 AUSTRIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 168 AUSTRIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 169 AUSTRIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 170 IRELAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 171 IRELAND BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 172 IRELAND ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 173 IRELAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 174 IRELAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 175 IRELAND ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 176 IRELAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 177 IRELAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 178 IRELAND HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 179 NETHERLANDS ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 180 NETHERLANDS BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 181 NETHERLANDS ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 182 NETHERLANDS ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 183 NETHERLANDS ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 184 NETHERLANDS ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 185 NETHERLANDS ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 186 NETHERLANDS ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 187 NETHERLANDS HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 188 SWITZERLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 189 SWITZERLAND BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 190 SWITZERLAND ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 191 SWITZERLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 192 SWITZERLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 193 SWITZERLAND ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 194 SWITZERLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 195 SWITZERLAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 196 SWITZERLAND HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 197 REST OF EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 198 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 199 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 200 ASIA-PACIFIC BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 201 ASIA-PACIFIC ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 202 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 203 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 204 ASIA-PACIFIC ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 205 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 206 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 207 ASIA-PACIFIC HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 208 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 209 CHINA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 210 CHINA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 211 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 212 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 213 CHINA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 214 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 215 CHINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 216 CHINA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 217 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 218 AUSTRALIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 219 AUSTRALIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 220 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 221 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 222 AUSTRALIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 223 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 224 AUSTRALIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 225 AUSTRALIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 226 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 227 JAPAN BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 228 JAPAN ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 229 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 230 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 231 JAPAN ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 232 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 233 JAPAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 234 JAPAN HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 235 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 236 SOUTH KOREA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 237 SOUTH KOREA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 238 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 239 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 240 SOUTH KOREA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 241 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 242 SOUTH KOREA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 243 SOUTH KOREA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 244 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 245 SINGAPORE BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 246 SINGAPORE ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 247 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 248 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 249 SINGAPORE ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 250 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 251 SINGAPORE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 252 SINGAPORE HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 253 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 254 INDIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 255 INDIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 256 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 257 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 258 INDIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 259 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 260 INDIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 261 INDIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 262 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 263 INDONESIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 264 INDONESIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 265 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 266 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 267 INDONESIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 268 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 269 INDONESIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 270 INDONESIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 271 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 272 PHILIPPINES BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 273 PHILIPPINES ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 274 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 275 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 276 PHILIPPINES ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 277 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 278 PHILIPPINES ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 279 PHILIPPINES HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 280 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 281 THAILAND BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 282 THAILAND ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 283 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 284 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 285 THAILAND ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 286 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 287 THAILAND ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 288 THAILAND HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 289 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 290 MALAYSIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 291 MALAYSIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 292 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 293 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 294 MALAYSIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 295 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 296 MALAYSIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 297 MALAYSIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 298 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 299 VIETNAM BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 300 VIETNAM ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 301 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 302 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 303 VIETNAM ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 304 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 305 VIETNAM ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 306 VIETNAM HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 307 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 308 TAIWAN BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 309 TAIWAN ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 310 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 311 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 312 TAIWAN ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 313 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 314 TAIWAN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 315 TAIWAN HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 316 REST OF ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 317 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 318 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 319 SOUTH AMERICA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 320 SOUTH AMERICA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 321 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 322 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 323 SOUTH AMERICA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 324 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 325 SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 326 SOUTH AMERICA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 327 BRAZIL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 328 BRAZIL BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 329 BRAZIL ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 330 BRAZIL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 331 BRAZIL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 332 BRAZIL ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 333 BRAZIL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 334 BRAZIL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 335 BRAZIL HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 336 ARGENTINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 337 ARGENTINA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 338 ARGENTINA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 339 ARGENTINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 340 ARGENTINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 341 ARGENTINA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 342 ARGENTINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 343 ARGENTINA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 344 ARGENTINA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 345 CHILE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 346 CHILE BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 347 CHILE ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 348 CHILE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 349 CHILE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 350 CHILE ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 351 CHILE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 352 CHILE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 353 CHILE HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 354 PERU ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 355 PERU BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 356 PERU ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 357 PERU ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 358 PERU ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 359 PERU ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 360 PERU ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 361 PERU ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 362 PERU HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 363 REST OF SOUTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 364 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY COUNTRY, 2018-2032 (USD THOUSAND)

TABLE 365 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 366 MIDDLE EAST AND AFRICA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 367 MIDDLE EAST AND AFRICA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 368 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 369 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 370 MIDDLE EAST AND AFRICA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 371 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 372 MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 373 MIDDLE EAST AND AFRICA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 374 SOUTH AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 375 SOUTH AFRICA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 376 SOUTH AFRICA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 377 SOUTH AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 378 SOUTH AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 379 SOUTH AFRICA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 380 SOUTH AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 381 SOUTH AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 382 SOUTH AFRICA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 383 EGYPT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 384 EGYPT BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 385 EGYPT ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 386 EGYPT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 387 EGYPT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 388 EGYPT ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 389 EGYPT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 390 EGYPT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 391 EGYPT HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 392 SAUDI ARABIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 393 SAUDI ARABIA BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 394 SAUDI ARABIA ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 395 SAUDI ARABIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 396 SAUDI ARABIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 397 SAUDI ARABIA ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 398 SAUDI ARABIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 399 SAUDI ARABIA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 400 SAUDI ARABIA HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 401 U.A.E. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 402 U.A.E. BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 403 U.A.E. ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 404 U.A.E. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 405 U.A.E. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 406 U.A.E. ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 407 U.A.E. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 408 U.A.E. ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 409 U.A.E. HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 410 KUWAIT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 411 KUWAIT BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 412 KUWAIT ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 413 KUWAIT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 414 KUWAIT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 415 KUWAIT ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 416 KUWAIT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 417 KUWAIT ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 418 KUWAIT HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 419 ISRAEL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

TABLE 420 ISRAEL BETA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 421 ISRAEL ALPHA EMITTERS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 422 ISRAEL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY SOURCES, 2018-2032 (USD THOUSAND)

TABLE 423 ISRAEL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY THERAPEUTIC APPLICATION, 2018-2032 (USD THOUSAND)

TABLE 424 ISRAEL ONCOLOGY IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 425 ISRAEL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY VECTOR TYPE, 2018-2032 (USD THOUSAND)

TABLE 426 ISRAEL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY END USER, 2018-2032 (USD THOUSAND)

TABLE 427 ISRAEL HOSPITALS IN ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY TYPE, 2018-2032 (USD THOUSAND)

TABLE 428 REST OF MIDDLE EAST AND AFRICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE, 2018-2032 (USD THOUSAND)

List of Figure

FIGURE 1 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SEGMENTATION

FIGURE 2 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: MULTIVARIATE MODELLING

FIGURE 7 CURVE LINE CHART, BY ISOTOPE

FIGURE 8 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 9 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: DBMR MARKET POSITION GRID

FIGURE 10 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: VENDOR SHARE ANALYSIS

FIGURE 11 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: END USER MARKET COVERAGE GRID

FIGURE 12 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SEGMENTATION

FIGURE 13 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: EXECUTIVE SUMMARY

FIGURE 14 STRATEGIC DECISIONS

FIGURE 15 TWO SEGMENTS COMPRISE THE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET, BY ISOTOPE 2024

FIGURE 16 NORTH AMERICA IS EXPECTED TO DOMINATE THE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET AND NORTH AMERICA IS EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2025 TO 2032

FIGURE 17 INCREASED EFFICACY OF TARGETED ALPHA AND BETA THERAPIES IS EXPECTED TO DRIVE THE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET IN THE FORECAST PERIOD

FIGURE 18 BETA EMITTERS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET IN 2025 & 2032

FIGURE 19 NORTH AMERICA IS THE FASTEST GROWING REGION FOR THE GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET IN 2025 & 2032

FIGURE 20 INCIDENCE BY CANCER SITE

FIGURE 21 CANCER MORTALITY RATE WITH CANCER SITE

FIGURE 22 DROC ANALYSIS

FIGURE 23 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, 2024

FIGURE 24 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, 2025 TO 2032 (USD THOUSAND)

FIGURE 25 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, CAGR (2025-2032)

FIGURE 26 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY ISOTOPE, LIFELINE CURVE

FIGURE 27 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, 2024

FIGURE 28 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, 2025 TO 2032 (USD THOUSAND)

FIGURE 29 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, CAGR (2025-2032)

FIGURE 30 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY SOURCES, LIFELINE CURVE

FIGURE 31 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, 2024

FIGURE 32 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, 2025 TO 2032 (USD THOUSAND)

FIGURE 33 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, CAGR (2025-2032)

FIGURE 34 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY THERAPEUTIC APPLICATION, LIFELINE CURVE

FIGURE 35 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, 2024

FIGURE 36 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, 2025 TO 2032 (USD THOUSAND)

FIGURE 37 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, CAGR (2025-2032)

FIGURE 38 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY VECTOR TYPE, LIFELINE CURVE

FIGURE 39 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, 2024

FIGURE 40 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, 2025 TO 2032 (USD THOUSAND)

FIGURE 41 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, CAGR (2025-2032)

FIGURE 42 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: BY END USER, LIFELINE CURVE

FIGURE 43 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: SNAPSHOT (2024)

FIGURE 44 GLOBAL ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2024 (%)

FIGURE 45 ASIA-PACIFIC ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2024 (%)

FIGURE 46 EUROPE ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2024 (%)

FIGURE 47 NORTH AMERICA ALPHA AND BETA EMITTERS BASED RADIOPHARMACEUTICALS MARKET: COMPANY SHARE 2024 (%)

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Industry Related Reports

Browse Related Pages

Testimonial
Claudio Rondena Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future
Request for TOC Speak to Analyst Free Sample Report Inquire Before Buy Now
Request a Call
Please select country
Please enter Contact No.
Please enter job tital
Please enter company name
Request for Demo
Please select country
Please enter Contact No.
Please enter job tital
Please enter company name
Office Number 402, Amanora
Chambers, Magarpatta Road, Hadapsar
Pune – 411028.

Reports

Market Insights

Support

Solutions

DMCA Protected © DataBridge - All Rights Reserved.

We Accept Payment